Blepharospasm Patients after Botulinum Toxin – Sleep Approach

Abstract

Background Blepharospasm is a focal dystonia that affects the orbicularis oculi muscles. The interest in nonmotor symptoms is due to their impact on quality of life.

Objective We evaluated the frequency of sleep disorders and circadian rhythm in a sample of Brazilian blepharospasm patients.

Methods A total of 51 patients, who met the clinical criteria for blepharospasm, evaluated by 2 specialists in movement disorders, were recruited from the outpatient clinic for movement disorders of two reference centers in the city of São Paulo: Universidade Federal de São Paulo and Hospital do Servidor Público do Estado de São Paulo. The selected 13 patients were evaluated from 13 days before to 13 days after using botulinum toxin. They were interviewed, underwent physical examination and actigraphy, and completed sleep diaries.

Results After using botulinum toxin, the group that reported sleep improvement exhibited a 50% decrease in sleep latency. There was no change in restless leg syndrome or circadian rhythm. Patients who reported no sleep improvement after using botulinum toxin presented poorer synchronization of the light-dark cycle.

Conclusion Blepharospasm patients have poor sleep quality. About 50% of the patients had sleep improvement after using botulinum toxin. The synchronization of the light-dark cycle should be influenced by this finding.

Keywords

blepharospasm - sleep - dystonia - circadian rhythm - actigraphy

Publikationsverlauf

Eingereicht: 19. Januar 2022

Angenommen: 21. Juni 2022

Artikel online veröffentlicht:
19. April 2023

• References

• 1 Defazio G, Hallett M, Jinnah HA, Conte A, Berardelli A. Blepharospasm 40 years later. Mov Disord 2017; 32 (04) 498-509.
• 2 Sun Y, Tsai PJ, Chu CL, Huang WC, Bee YS. Epidemiology of benign essential blepharospasm: A nationwide population-based retrospective study in Taiwan. PLoS One 2018; 13 (12) e0209558.
• 3 Hwang CJ, Eftekhari K. Benign Essential Blepharospasm: What We Know and What We Don't. Int Ophthalmol Clin 2018; 58 (01) 11-24.
• 4 Avanzino L, Martino D, Marchese R. et al. Quality of sleep in primary focal dystonia: a case-control study. Eur J Neurol 2010; 17 (04) 576-581.
• 5 Hertenstein E, Tang NK, Bernstein CJ, Nissen C, Underwood MR, Sandhu HK. Sleep in patients with primary dystonia: A systematic review on the state of research and perspectives. Sleep Med Rev 2016; 26: 95-107.
• 6 Gonçalves BS, Adamowicz T, Louzada FM, Moreno CR, Araujo JF. A fresh look at the use of nonparametric analysis in actimetry. Sleep Med Rev 2015; 20: 84-91.
• 7 Albanese A, Bhatia K, Bressman SB. et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013; 28 (07) 863-873.
• 8 Hallett M, Evinger C, Jankovic J, Stacy M. BEBRF International Workshop. Update on blepharospasm: report from the BEBRF International Workshop. Neurology 2008; 71 (16) 1275-1282.
• 9 Peckham EL, Lopez G, Shamim EA. et al. Clinical features of patients with blepharospasm: a report of 240 patients. Eur J Neurol 2011; 18 (03) 382-386.
• 10 Lee JM, Baek JS, Choi HS, Kim SJ, Jang JW. Clinical Features of Benign Essential Blepharospasm in Korean Patients. Korean J Ophthalmol 2018; 32 (05) 339-343.
• 11 Yang J, Song W, Wei Q. et al. Screening for Cognitive Impairments in Primary Blepharospasm. PLoS One 2016; 11 (08) e0160867.
• 12 Ali SM, Alqutaibi AY, Aboalrejal A, Elawady DM. Botulinum toxin and occlusal splints for the management of sleep bruxism in individuals with implant overdentures: A randomized controlled trial. Saudi Dent J 2021; 33 (08) 1004-1011.
• 13 Veverka T, Hluštík P, Otruba P. et al. Cortical somatosensory processing after botulinum toxin therapy in post-stroke spasticity. Medicine (Baltimore) 2021; 100 (25) e26356.
• 14 Weiss D, Hieber L, Sturm J. et al. Health-related quality of life outcomes from botulinumtoxin treatment in blepharospasm. Clin Neurol Neurosurg 2018; 172: 130-133.